A new study on prostate-specific antigen (PSA) testing offers some quantification of its reliability in assessing the effectiveness of chemotherapy for advanced prostate cancer.
Researchers at the University of Michigan's Comprehensive Cancer Center in Ann Arbor studied 62 patients with advanced prostate cancer who received PSA tests after undergoing 8 weeks of chemotherapy. They found that men whose PSA levels had declined at least 50% had a median survival time of 91 weeks, compared with 38 weeks for men whose PSA levels had not declined by 50% or more.
Voelker R. PSA and Chemotherapy. JAMA. 1998;279(20):1599. doi:10.1001/jama.279.20.1599-JQU80002-2-1
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: